This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 9 EPO patents. Top assignee: Pramana Pharmaceuticals Inc.. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Mikhail Chafeev: Innovator in Pharmaceutical Compounds
Introduction
Mikhail Chafeev is a notable inventor based in Khimki, Russia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific receptors in the body. His work has implications for treating various metabolic disorders, including Type 2 diabetes mellitus.
Latest Patents
Mikhail Chafeev holds 1 patent for his invention titled "Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119." This patent describes compounds that can be used in the treatment of diseases associated with GPR119 dysregulation, including Type 2 diabetes and related metabolic disorders.
Career Highlights
Throughout his career, Mikhail has worked with prominent companies in the pharmaceutical industry. He has been associated with Pramana Pharmaceuticals Inc. and AbbVie Inc., where he has contributed to research and development efforts aimed at improving health outcomes through innovative therapies.
Collaborations
Mikhail Chafeev has collaborated with several professionals in his field, including Tarek Suhayl Mansour and Mikhail Yudin. These collaborations have likely enhanced his research and development capabilities, leading to advancements in pharmaceutical innovations.
Conclusion
Mikhail Chafeev is a distinguished inventor whose work in pharmaceutical compounds has the potential to impact the treatment of metabolic disorders significantly. His contributions to the field exemplify the importance of innovation in healthcare.